Albatroz Therapeutics

Executive Summary

Albatroz Therapeutics is a Singapore-based biotechnology company pioneering first-in-class therapeutic antibodies targeting Calnexin, a novel regulator of extracellular matrix (ECM) degradation. By blocking Calnexin, the company aims to preserve ECM integrity, thereby inhibiting tumor growth and metastasis in oncology while preventing tissue damage in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. This approach offers potential efficacy without the toxicity associated with current standard-of-care treatments. Founded in 2020, Albatroz is currently in the preclinical stage and operates with a lean team of 10-50 employees. The company's platform addresses multiple high-need indications, positioning it as a versatile player in the oncology and autoimmune space. However, as a preclinical entity with no disclosed funding rounds or valuation, its risk profile remains high, and the path to clinical validation is still ahead. The development of Calnexin-targeted antibodies represents a differentiated strategy in the competitive landscape of ECM-modulating therapies, with promise for both monotherapy and combination regimens.

Upcoming Catalysts (preview)

• H2 2026Presentation of preclinical proof-of-concept data at a major scientific conference70% success
• H1 2027Completion of IND-enabling studies and submission of Investigational New Drug application50% success
• 2026-2027Announcement of a strategic partnership or licensing deal for co-development40% success